Dendreon, 2.875% 15jan2016, USD (Conv.) (FIGI BBG001DCSH80, WKN A1GLF9)
国内債券, 転換社債, Senior Unsecured
国内債券, 転換社債, Senior Unsecured
|
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small ...
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.
|
|
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
167 970
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡